Could a simple pill keep nasopharyngeal cancer away?

NCT ID NCT07248670

Ongoing Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial tests whether adding a low-dose chemotherapy pill (capecitabine) after standard chemoradiation helps prevent cancer from returning in people with high-risk nasopharyngeal cancer. About 252 participants with stage T1-2N1M0 disease and certain high-risk features will be randomly assigned to receive capecitabine or just observation. The study focuses on those who still have detectable EBV DNA during radiation, a marker of higher risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine (a chemotherapy drug taken by mouth)
What this could lead to: If successful, adding capecitabine after standard chemoradiation could lower the chance of cancer returning in high-risk patients.
What could go wrong: This is a Phase III trial, but only for a specific high-risk group. The benefit may be modest, and capecitabine can cause side effects like hand-foot syndrome or diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.